Finance
Bill Ackman says it’s one of the best times in a long time to buy quality stocks
Key Points Bill Ackman urged investors to look past macro fears and lean into what he sees as deeply discounted opportunities. His bullish stance comes at a time when markets have been rattled by rising energy prices and sticky inflation concerns. Source
Read More
Fed Governor Miran still backs cuts, says interest rates could be ‘about a point’ lower this year
Key Points Federal Reserve Governor Stephen Miran continued his campaign for lower interest rates, telling CNBC that policymakers should disregard the current energy price spike. He told CNBC that he continues to think “we could be about a point easier, gradually done over the course of a year.” Source
Read More
Watch Fed Chair Jerome Powell speak live to an economics class at Harvard
[The stream is slated to start at 10:30 a.m. ET. CNBC Television will start the stream when the event begins. Please refresh the page if you do not see a player above.] Federal Reserve Chair Jerome Powell speaks Monday to the Harvard University Principles of Economics class. This will be one of Powell’s final scheduled […]
Read More
Stocks making the biggest moves premarket: Sysco, CrowdStrike, Alcoa & more
Check out the companies making the biggest moves premarket: Sysco — The wholesale food distributor fell 4.5% after it agreed to buy Jetro Restaurant Depot for a total enterprise value of $29.1 billion. The deal is expected to close in Sysco’s 2027 fiscal third quarter, with the company calling the transaction “immediately accretive.” Avis — […]
Read More
As stocks and bonds fall, and oil hits $100, a futures trade that boomed in 2022 may again be a winner
ETF Edge As stocks and bonds fall, and oil hits $100, a futures trade that boomed in 2022 may again be a winner Published Sat, Mar 28 20268:00 AM EDT Krysta Escobar WATCH LIVE Source
Read More
Stocks making the biggest moves premarket: AstraZeneca, Unity Software, Coinbase & more
Check out the companies making the biggest moves premarket: AstraZeneca — The pharma giant rose 3% after its experimental drug, tozorakimab, was found to meaningfully reduce flare-ups in cases of chronic obstructive pulmonary disease. The drug delivered the results in two late-stage trials, and the company said full results will be delivered at an upcoming […]
Read More